Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Development of Immunocompetence

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...

siRNA - Small Interfering RNAs

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Eliminating Inappropriate Postoperative Antibiotics: A Stepped-Wedge Cluster Randomized Trial.

Pediatrics·2026

Same author

Variability in Recommendations for Measles, Mumps, Rubella Vaccination and Vitamin A Administration in the Setting of Measles Outbreaks.

Journal of the Pediatric Infectious Diseases Society·2026

Same author

Unsung Healthcare Heroes for Children.

Narrative inquiry in bioethics·2026

Same author

Assessing COVID-19 Testing Strategies in K-12 Schools in Underserved Populations.

Journal of public health management and practice : JPHMP·2026

Same author

Multicenter Evaluation of Ceftazidime/Avibactam in Pediatric Patients Across the United States: Real-World Insights into the Management of Drug-Resistant Gram-Negative Infections.

Open forum infectious diseases·2026

Same author

A Multicomponent Strategy to Increase Human Papillomavirus Vaccination Rates in Primary Care: A Cluster Randomized Clinical Trial.

JAMA network open·2026

Search research articles

Related Experiment Video

Updated: Jun 28, 2025

Intravenous Injections in Neonatal Mice

Intravenous Injections in Neonatal Mice

Published on: November 11, 2014

Balanced on the Biggest Wave: Nirsevimab for Newborns.

Christopher McPherson, Christine R Lockowitz, Jason G Newland

Neonatal Network : NN

|April 10, 2024

Summary

A new monoclonal antibody, nirsevimab, offers season-long protection against severe respiratory syncytial virus (RSV) disease in infants with a single dose. This advancement provides a more convenient and effective option for preventing infant hospitalizations due to RSV.

Keywords:

RSV immunization infection monoclonal antibodies nirsevimab palivizumab respiratory syncytial virus

More Related Videos

Intracerebroventricular and Intravascular Injection of Viral Particles and Fluorescent Microbeads into the Neonatal Brain

Intracerebroventricular and Intravascular Injection of Viral Particles and Fluorescent Microbeads into the Neonatal Brain

Published on: July 24, 2016

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis

Published on: August 12, 2020

Related Experiment Videos

Last Updated: Jun 28, 2025

Intravenous Injections in Neonatal Mice

Intravenous Injections in Neonatal Mice

Published on: November 11, 2014

Intracerebroventricular and Intravascular Injection of Viral Particles and Fluorescent Microbeads into the Neonatal Brain

Intracerebroventricular and Intravascular Injection of Viral Particles and Fluorescent Microbeads into the Neonatal Brain

Published on: July 24, 2016

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis

Published on: August 12, 2020

Area of Science:

Pediatrics
Immunology
Virology

Background:

Respiratory syncytial virus (RSV) is a major cause of infant hospitalizations in the US, affecting nearly all children by age two.
Severe RSV disease can lead to long-term health issues like asthma and delayed speech development.
Existing interventions like palivizumab are costly and require multiple doses, limiting their widespread use.

Purpose of the Study:

To evaluate the efficacy and safety of nirsevimab, a novel monoclonal antibody, for preventing severe RSV disease in infants.
To assess the potential of nirsevimab as a single-dose, season-long preventative measure against RSV hospitalization.

Main Methods:

Conducted four landmark randomized controlled trials involving healthy and high-risk infants (preterm and term).
Nirsevimab targets the RSV prefusion F protein's Ø antigenic site.
Monitored efficacy in reducing medically attended RSV disease and hospitalizations, alongside safety profiles.

Main Results:

Nirsevimab significantly reduced the risk of medically attended RSV disease (NNT 14-24) and hospitalization (NNT 33-63).
A single dose provided protection for an entire 5-month RSV season.
Observed rare side effects, primarily mild rash and injection site reactions.

Conclusions:

Nirsevimab is an effective and safe single-dose preventative therapy for severe RSV disease in infants.
Recent CDC recommendations support nirsevimab for infants younger than 8 months and high-risk infants aged 8-19 months.
Equitable distribution and multidisciplinary collaboration are crucial for successful implementation of nirsevimab therapy.